Exchange Traded Concepts LLC Has $836,000 Stock Holdings in DexCom, Inc. (NASDAQ:DXCM)

Exchange Traded Concepts LLC trimmed its position in DexCom, Inc. (NASDAQ:DXCM) by 12.4% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 10,750 shares of the medical device company’s stock after selling 1,526 shares during the quarter. Exchange Traded Concepts LLC’s holdings in DexCom were worth $836,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Versant Capital Management Inc bought a new position in shares of DexCom in the 4th quarter valued at about $25,000. Riverview Trust Co boosted its stake in DexCom by 100.4% in the third quarter. Riverview Trust Co now owns 463 shares of the medical device company’s stock valued at $31,000 after acquiring an additional 232 shares during the last quarter. RPg Family Wealth Advisory LLC acquired a new stake in DexCom during the 3rd quarter worth $57,000. Covestor Ltd raised its position in shares of DexCom by 53.7% during the 3rd quarter. Covestor Ltd now owns 959 shares of the medical device company’s stock valued at $64,000 after acquiring an additional 335 shares during the last quarter. Finally, MassMutual Private Wealth & Trust FSB lifted its stake in shares of DexCom by 46.7% in the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 833 shares of the medical device company’s stock valued at $65,000 after purchasing an additional 265 shares during the period. 97.75% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently commented on the company. Citigroup lifted their price objective on DexCom from $85.00 to $91.00 and gave the stock a “buy” rating in a research note on Wednesday, December 11th. Royal Bank of Canada lowered their price target on DexCom from $120.00 to $115.00 and set an “outperform” rating for the company in a research note on Friday, October 25th. JPMorgan Chase & Co. lifted their price objective on shares of DexCom from $75.00 to $85.00 and gave the stock a “neutral” rating in a research note on Friday, October 25th. Wells Fargo & Company upped their target price on shares of DexCom from $90.00 to $94.00 and gave the company an “overweight” rating in a research note on Wednesday, December 11th. Finally, Robert W. Baird raised shares of DexCom from a “neutral” rating to an “outperform” rating and lifted their price target for the stock from $86.00 to $104.00 in a research report on Thursday, January 16th. Five investment analysts have rated the stock with a hold rating, twelve have issued a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $99.29.

Insider Activity at DexCom

In other news, EVP Sadie Stern sold 4,259 shares of the company’s stock in a transaction that occurred on Wednesday, November 20th. The stock was sold at an average price of $74.73, for a total transaction of $318,275.07. Following the sale, the executive vice president now owns 71,192 shares in the company, valued at $5,320,178.16. This represents a 5.64 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this link. Insiders own 0.30% of the company’s stock.

DexCom Trading Up 0.9 %

DexCom stock opened at $88.30 on Wednesday. The company has a debt-to-equity ratio of 1.23, a current ratio of 2.46 and a quick ratio of 2.12. The firm has a 50-day moving average of $79.73 and a 200-day moving average of $76.70. The company has a market cap of $34.49 billion, a price-to-earnings ratio of 52.87, a P/E/G ratio of 2.23 and a beta of 1.12. DexCom, Inc. has a one year low of $62.34 and a one year high of $142.00.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.